News

ISIDORE User’s Conference

15. 04. 2024 Event

28 May 2024, online / Discover groundbreaking scientific research in infectious diseases at the ISIDORe project’s online scientific conference. Explore projects supported by ISIDORe over the past two years, including studies on COVID-19 variants, Mpox, and other priority pathogens. Register now for free to join the conference and connect with leading experts in the field.…

6th CCP Phenogenomics Conference 2024

27. 03. 2024 Event

17 – 18 September 2024, Prague, Czech Republic / REGISTRATION IS OPEN NOW ! Conference website DEADLINES:

Upgrade of the large research infrastructure CCP III

25. 03. 2024 Information News

The goal of the project (ID: CZ.02.01.01/00/23_015/0008189) is to modernize the large research infrastructure of the Czech Center for Phenogenomics with the aim of maintaining its competitiveness and expanding the portfolio of services. The project comprises of three key activities (KA): KA1 – Project management KA2 – Modernization and upgrade of large research infrastructure KA3…

CCP succeeded in the EIC Transition call

21. 03. 2024 News PR

Czech Centre for Phenogenomics (Institute of Molecular Genetics of the Czech Academy of Sciences), which is a partner in the project TREM2MEDS – Towards the clinical implementation of TREM2 microglia engineering for treating dementia, succeeded as the only applicant from the Czech Republic in the EIC Transitions call. TREM2MEDS (coordinator: Universita degli Studi di Padova, Italy)…

Apply for CCP services: Generation of precision cancer mouse models using CRISPR-Cas9 and In-depth cancer-based phenotyping of cancer mouse models

27. 02. 2024 Call News

Open Call for Transnational Service Provision under the canSERV Open Call The researchers are welcome to apply to a portfolio of services offered by canSERV to address the research needs of the entire oncology developmental pipeline. CCP offers following services in this call: For more information visit canSERV website. Submission Deadline: 21 May 2024, 2pm…

IMPC Spring 2024 Meeting – ‘Beyond the Genome’

23. 02. 2024 Event

28 – 30 April 2024, Cape Town, South Africa / The first ever IMPC “Spring” Meeting to be held in Africa and aims to convene leading international experts to deliver overview lectures that provide a global perspective on our topic: “Beyond the Genome”. Advances in nucleic acid-based therapies, based on the conventional coding genome, but…

Updated acknowledgement of CCP in research outputs

19. 02. 2024 Information News

The Czech Centre for Phenogenomics receives funding from public providers, which allows CCP to offer state-of-the-art services and technologies to its users. Therefore, all the work performed at CCP should be acknowledged by users in their outputs (publications, presentations etc.). This acknowledgement provides an evidence of the impact of CCP on quality of research and…

ASGENT continues supporting CCP research on Angelman syndrome in 2024

16. 02. 2024 Information News

On the occasion of the International Angelman Syndrome Day, Radislav Sedlacek, director of the Czech Centre fo Phenogenomics, received yesterday a cheque in the amount of CZK 1 million for the continuation of Angelman syndrome research using mouse models from the Association of Gene Therapy (ASGENT), which has long supported this research.At the same time,…

Rare Disease Day 2024

15. 02. 2024 Event

29 February 2024 / Raising awareness and generating change for the 300 million people worldwide living with a rare disease, their families and carers. https://www.rarediseaseday.org/ Informace o aktivitách v České republice na webu České asociace pro vzácná onemocnění.

12th European Conference on Rare Diseases and Orphan Products

15. 02. 2024 Event

15 – 16 May 2024, hybrid event / The ECRD is the largest, patient-led, rare disease policy-shaping event held in Europe. By bringing together people with rare diseases and patient advocates, policy makers, healthcare industry representatives, clinicians, regulators and Member State representatives, EURORDIS harnesses the power of this extensive network to shape goal-driven rare disease…